Baxter on Oct. 8 said it has resumed shipments of IV products to hospitals and dialysis patients after a temporary week-long hold and is inspecting finished goods to support current allocations. Baxter also said several of the manufacturer’s global plants are ramping production to meet U.S. needs and expect to receive product from the sources throughout October.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
